Search
Medetomidine
go.drugbank.com/drugs/DB11428ExperimentalVet approvedThe drug has been developed by Orion Pharma. In the United States, it is currently approved for its veterinary use in dogs and distributed by Pfizer Animal Health. … In Canada, medetomidine is distributed by Novartis Animal Health. The marketed product is a racemic mixture of two stereoisomers from which dexmedetomidine is the main active isomer.
Rocuronium
go.drugbank.com/drugs/DB00728ApprovedInvestigationalRocuronium (rapid onset-curonium) is a desacetoxy analogue of vecuronium with a more rapid onset of action. It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotra...
Exenatide
go.drugbank.com/drugs/DB01276ApprovedInvestigationalExenatide is a glucagon-like peptide-1 (GLP-1) analog . It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control . Exenatide was given FDA appro...
Agalsidase alfa
go.drugbank.com/drugs/DB15874ApprovedInvestigationalAgalsidase alfa is a recombinant human α-galactosidase A similar to agalsidase beta. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater b...
Cefuroxime
go.drugbank.com/drugs/DB01112ApprovedInvestigationalBroad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus.
Pyrvinium
go.drugbank.com/drugs/DB06816ApprovedInvestigationalWithdrawnPyrvinium is an anthelmintic effective for pinworms. Several forms of pyrvinium have been prepared with variable counter anions, such as halides, tosylate, triflate and pamoate. Pyrvinum's anti-cancer properties are currently under inves...
Orbifloxacin
go.drugbank.com/drugs/DB11443ExperimentalVet approvedIt is marketed by Schering-Plough Animal Health and approved for certain infections in dogs.
DLO6002
go.drugbank.com/drugs/DB05179ExperimentalDLO6002 is developed by Summit Corporation and is in phase I of clinical trials for the treatment of Parkinson's disease.
Domofenogene zalfaparvovec
go.drugbank.com/drugs/DB16810InvestigationalDomofenogene zalfaparvovec, formerly known as BMN-307, is an investigational AAV5-phenylalanine hydroxylase (PAH) gene therapy developed by BioMarin Pharmaceutical.
Gantacurium
go.drugbank.com/drugs/DB05710InvestigationalIt is being developed by Avera Pharmaceuticals.